Last reviewed · How we verify

NCT07017855: STAR-4VT

Stereotactic Radiosurgery as Second-line Therapy for Ventricular Tachycardia

Not yet recruiting NA Last updated 12 June 2025
What this trial tests

NA trial testing Stereotactic Arrhythmia Radioablation (STAR) in Ventricular Tachycardia, Monomorphic in 150 participants. Not yet recruiting.

Timeline
1 July 2025
Primary endpoint
1 May 2027
1 November 2028

Quick facts

Lead sponsorMedical University of Silesia
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment150
Start date1 July 2025
Primary completion1 May 2027
Estimated completion1 November 2028
Sites1 location across Poland

Drugs / interventions tested

Conditions studied

Sponsor

Medical University of Silesia

Who can join

18 and older, any sex, with Ventricular Tachycardia, Monomorphic or Ventricular Tachycardia, Sustained. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to compare the efficacy and safety of treating recurrent sustained Ventricular Tachycardia (sVT) after prior Catheter Ablation (CA) in patients with Implanted Cardioverter-Defibrillator (ICD) between re-do of conventional endocardial CA and Stereotactic Arrhythmia Radioablation (STAR).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Medical University of Silesia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07017855.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing